Skip to content
Search

Latest Stories

Gilead to ship 450,000 remdesivir vials to India as Covid-19 cases surge

GILEAD SCIENCES Inc has said that it will give India at least 450,000 vials of its antiviral drug remdesivir and help boost production, as the world's second-most populous country reels from surging coronavirus cases.

Remdesivir is approved in India for restricted emergency use to treat severe Covid-19 cases, but hospitals are facing supply shortages due to indiscriminate use and the drug is being sold at over 10 times its listed price in the black market.


The shortage has raised concerns about hoarding as people queue up outside clinics and hospitals to buy the drug and millions take to social media to secure supplies.

Earlier this month, India banned the export of the drug and the active pharmaceutical ingredients (API) used to make it.

Seven Indian companies have licensed the drug from Gilead, with an installed capacity of about 3.9 million units per month. Gilead has said that all of them were scaling up their batch sizes and adding new manufacturing facilities and local contract manufacturers.

There are doubts about the drug's effectiveness in treating Covid-19. The WHO in November issued a conditional recommendation against the use of remdesivir in hospitalised patients, but India has continued to use it.

A senior Indian government health official said last week that remdesivir is only for those patients who need oxygen. "I am appealing that the hype over this medicine should be decreased, and it should be used in a rational manner," Vinod Kumar Paul said.

On Monday (26), Russian pharmaceutical firm Pharmasyntez said it was ready to ship up to 1 million packs of remdesivir to India by end-May once it received the Russian government's approval.

India has reported more than 300,000 new Covid-19 cases per day over the past six days. It has an official tally of 17.31 million infections and 195,123 deaths, health ministry data showed, although health experts say the figures likely run higher.

Nations including Britain, Germany and the United States have pledged support, while the World Health Organization termed the situation as "beyond heartbreaking".

More For You

 ISKCON's UK birthplace

The building holds deep spiritual importance as ISKCON's UK birthplace

iskconnews

ISKCON reclaims historic London birthplace for £1.6 million after 56 years

Highlights

  • ISKCON London acquires 7 Bury Place, its first UK temple site opened in 1969, for £1.6 million at auction.
  • Five-storey building near British Museum co-signed by Beatle George Harrison who helped fund original lease.
  • Site to be transformed into pilgrimage centre commemorating ISKCON's pioneering work in the UK.
ISKCON London has successfully reacquired 7 Bury Place, the original site of its first UK temple, at auction for £1.6 m marking what leaders call a "full-circle moment" for the Krishna consciousness movement in Britain.

The 221 square metre freehold five-storey building near the British Museum, currently let to a dental practice, offices and a therapist, was purchased using ISKCON funds and supporter donations. The organisation had been searching for properties during its expansion when the historically significant site became available.

The building holds deep spiritual importance as ISKCON's UK birthplace. In 1968, founder A.C. Bhaktivedanta Swami Prabhupada sent three American couples to establish a base in England. The six devotees initially struggled in London's cold, using a Covent Garden warehouse as a temporary temple.

Keep ReadingShow less